Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 9Urinary Bladder Neoplasms 4Urethral Neoplasms 4Melanoma 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Osteosarcoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Carcinoma, Hepatocellular 3Urogenital Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Penile Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Lung Neoplasms 2HIV Infections 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

Specimen Handling 3Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2olaparib 1durvalumab 1cediranib 1capivasertib 1cabozantinib 1adavosertib 1Taxes 1Radiation 1Platinum 1Paclitaxel 1Immunoglobulin G 1Fluid Therapy 1Disulfides 1Dasatinib 1Congresses as Topic 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Endometrioid × cabozantinib × Clear all
NCT01935934 2025-10-01

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
102 enrolled 14 charts

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡